Economic impact as a result of the performance of a committee of pharmacy and therapeutics: the experience of Mato Grosso.

Growing demand for skilled health care, changes in the population's demographic and epidemiological profile, and the emergence of new technologies in the health market has made technology selection an important strategy for ensuring access to safe products and services for the population to weigh the sustainability of health systems. The purpose of this work was to demonstrate the economic impact, from the perspective of the State Health Secretariat of Mato Grosso, of the activities carried out by a Standing Committee on Pharmacy and Therapeutics (CPFT) with transparent action based on the assessment of health technologies. To this end, the behavior of expenditures on drugs not included in the lists of essential medicines of the Unified Health System during and after the validity of an administrative route planned to give the population access to this type of medicines was evaluated. In this sense, expenses with direct disbursements for the purchase of medicines intended to meet State Ordinance No. 172/2010 were raised, as well as lawsuits with the aid of the Integrated Planning, Accounting and Finance System - FIPLAN. In order to bring the amounts spent to the present day, an inflationary adjustment was applied based on the Broad National Consumer Price Index. The findings pointed to expressive and constant annual average expenses, with non-standardized drugs during the administrative route, with consequent reduction of expenses with lawsuits from their revocation. This period coincided with the submission of several works of CPFT - MT, especially the state list of drugs and construction and updating of state clinical protocols, resulting in a saving of 53%. The results corroborate with previous research showing that a qualified and transparent technology selection process can yield, in addition to clinical benefits, economic gains for health systems.

Key words: Drugs, Essential; Pharmaceutical Services; Pharmacy and Therapeutics Committee.